Abstract
Significant advances in therapeutic applications of proteins and peptides have brought new challenges in the field of drug development. Ordered protein aggregation known as amyloid formation has recently emerged as a universal phenomenon due to extensive research in protein folding and amyloid diseases. The amyloid represents a new generic structure characterized by cross-β-sheet formation in its core, which implies that any polypeptide can adopt this conformation under amyloid-prone conditions. Some widely-used biopharmaceuticals such as insulin, glucagon, amylin and calcitonin have been shown to form amyloids and this list may be significantly extended upon further research. Compared to soluble precursor proteins and amorphous aggregates amyloids gain new properties such as remarkable stability and protease resistance, polymorphism, selfpropagation via seeding and cross-seeding, cytotoxicity and induced immunogenicity. Some of them can be hazardous in biopharmaceutical applications. The causes of amyloid aggregation and strategies for its prevention are reviewed here. They utilize the current knowledge of amyloid properties, structure-based design principles and protein chemistry. Once these challenges are met, they will ultimately lead to safer and surer pharmaceuticals.
Keywords: amyloid, nucleation, cross-seeding, cytotoxicity, inhibitors, lysozyme, biopharmaceuticals
Current Medicinal Chemistry
Title: A False Paradise - Mixed Blessings in the Protein Universe: The Amyloid as a New Challenge in Drug Development
Volume: 14 Issue: 11
Author(s): Ludmilla Morozova-Roche and Mantas Malisauskas
Affiliation:
Keywords: amyloid, nucleation, cross-seeding, cytotoxicity, inhibitors, lysozyme, biopharmaceuticals
Abstract: Significant advances in therapeutic applications of proteins and peptides have brought new challenges in the field of drug development. Ordered protein aggregation known as amyloid formation has recently emerged as a universal phenomenon due to extensive research in protein folding and amyloid diseases. The amyloid represents a new generic structure characterized by cross-β-sheet formation in its core, which implies that any polypeptide can adopt this conformation under amyloid-prone conditions. Some widely-used biopharmaceuticals such as insulin, glucagon, amylin and calcitonin have been shown to form amyloids and this list may be significantly extended upon further research. Compared to soluble precursor proteins and amorphous aggregates amyloids gain new properties such as remarkable stability and protease resistance, polymorphism, selfpropagation via seeding and cross-seeding, cytotoxicity and induced immunogenicity. Some of them can be hazardous in biopharmaceutical applications. The causes of amyloid aggregation and strategies for its prevention are reviewed here. They utilize the current knowledge of amyloid properties, structure-based design principles and protein chemistry. Once these challenges are met, they will ultimately lead to safer and surer pharmaceuticals.
Export Options
About this article
Cite this article as:
Morozova-Roche Ludmilla and Malisauskas Mantas, A False Paradise - Mixed Blessings in the Protein Universe: The Amyloid as a New Challenge in Drug Development, Current Medicinal Chemistry 2007; 14 (11) . https://dx.doi.org/10.2174/092986707780597989
DOI https://dx.doi.org/10.2174/092986707780597989 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Germline Genetics of the p53 Pathway Affect Longevity in a Gender Specific Manner
Current Aging Science Pathogenesis in Childhood Idiopathic Nephrotic Syndrome: An Update of Patchwork
Current Pediatric Reviews The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Current Gene Therapy Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Pharmacogenomics of Osteoporosis
Current Pharmacogenomics Nanoceria: A Novel Cytoprotective Drug Delivery Carrier
Current Nanomedicine Relation of Obesity to Cognitive Function: Importance of Central Obesity and Synergistic Influence of Concomitant Hypertension. The Framingham Heart Study
Current Alzheimer Research Mass Spectrometry-Based Strategies for Screening of Bioactive Natural Products
Combinatorial Chemistry & High Throughput Screening (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Homocysteine Levels in Autism Spectrum Disorder: A Clinical Update
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin Therapy, Insulin Resistance and Vascular Dysfunction
Current Vascular Pharmacology The Endocrine Function of Adipose Tissue
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology